“Pfizer and Eisai Will Continue to Promote Aricept, but add Lyrica to the Collaboration” (The Pink Sheet)
A potential sticking point in Pfizer’s acquisition of Wyeth has been resolved – the big drug maker and Eisai have agreed to continue co-promoting Aricept (donepezil) in the U.S., Europe and Japan. However, Eisai will regain full Japanese rights to the Alzheimer’s blockbuster at the end of 2012, while the rest of the collaboration will remain in place until 2022.
This is copyright protected information, to receive the full article, please click here to sign up and register.
“Pfizer Expects Speedy Integration Of Wyeth, R&D Head Mackay Says” (The Pink Sheet)
Drug sponsors trying to gauge how FDA’s new leadership might handle controversies surrounding their NDAs received some sobering insight when the agency released its internal assessment of the approval of ReGen Biologics’ Menaflex knee repair device.
This is copyright protected information, to receive the full article, please click here to sign up and register.
“Abbott, Johnson & Johnson bulk up in Europe” (EuroInvestor)
“AMBI(R) Skincare Announces Winners of the AMBI(R) Scholarship in Science & Medicine” (InterestAlert)
“Ligand receiving $500,000 payment from Glaxo” (CNBC)
“M&A boosts Wall Street on deals from Xerox, Abbott” (Reuters)
“More Women Chose Prophylactic Mastectomy” (MedPageToday)
“J&J’s Knockout Drug” (The Motley Fool)
SUBSCRIBE